Colivicchi Furio, Fabbri Gianna, Oliva Fabrizio, Abrignani Maurizio Giuseppe, Arca Marcello, Averna Maurizio, Catapano Alberico Luigi, Ceseri Martina, Di Fusco Stefania Angela, Di Lenarda Andrea, Fattirolli Francesco, Gabrielli Domenico, Gonzini Lucio, Gulizia Michele Massimo, Riccio Carmine, Temporelli Pier Luigi, Aloia Antonio, Alonzo Alessandro, Aschieri Daniela, Barbato Emanuele, Bertoli Daniele, Calabrò Paolo, Calò Leonardo, Carugo Stefano, Crisci Vincenzo, La Rosa Giuseppe, Maffei Simone, Navazio Alessandro, Pavan Daniela, Scelza Nicola, Scicchitano Pietro, Themistoclakis Sakis, Maggioni Aldo Pietro
Clinical and Rehabilitation Cardiology Department, San Filippo Neri Hospital, ASL Roma 1, Roma, Italy.
ANMCO Research Center, Heart Care Foundation, Firenze, Italy.
Int J Cardiol. 2025 Aug 15;433:133290. doi: 10.1016/j.ijcard.2025.133290. Epub 2025 Apr 19.
To narrow the gap between guidelines recommendation for secondary cardiovascular prevention and clinical practice, we designed a national project based on educational programs and patient data collection.
BRING-UP Prevention is an observational, prospective, multicentre study on patients with an atherothrombotic event enrolled in 2 phases: an educational intervention followed by two 3-months data collection, followed by 6 and 12-month follow-up, when the primary, secondary and exploratory endpoints will be evaluated. Clinical characteristics, treatments and target achievement for LDL cholesterol and other modifiable risk factors at baseline are reported in this manuscript.
From September 2023 to February 2024, 189 cardiology centers included 4790 patients, 2500 hospitalized, and 2290 managed as outpatients. Of the 4790 patients, 98 % had CAD, 6.1 % CVD, and 6.9 % PAD. Mean age was 67 ± 11 years, 20 % were females. Patients with LDL-C levels <55 mg/dL were 32.6 %. Patients at target for blood pressure were 39.2 %. Diabetic patients were 27.5 %, HbA1c <7 % was reported in 43.5 % of them. Statins prescription increased from 69 % at entry to 96 % at discharge/end of visit. In 74.5 % of patients, statins were prescribed in combination with ezetimibe. PCSK9-i or inclisiran were prescribed in a low rate of patients.
These data show that a low percentage of patients was at goal for LDL-C level and blood pressure. The 6-month follow-up visit will allow us to evaluate the changes in modifiable risk factors.
为缩小二级心血管预防指南建议与临床实践之间的差距，我们基于教育项目和患者数据收集设计了一个全国性项目。
BRING-UP预防研究是一项针对动脉粥样硬化血栓形成事件患者的观察性、前瞻性、多中心研究，分两个阶段进行：一个教育干预阶段，随后是两次为期3个月的数据收集，接着是6个月和12个月的随访，届时将评估主要、次要和探索性终点。本文报告了基线时的临床特征、治疗情况以及低密度脂蛋白胆固醇和其他可改变危险因素的目标达成情况。
2023年9月至2024年2月，189个心脏病中心纳入了4790例患者，其中2500例住院，2290例为门诊治疗。在4790例患者中，98%患有冠心病，6.1%患有心血管疾病，6.9%患有外周动脉疾病。平均年龄为67±11岁，女性占20%。低密度脂蛋白胆固醇水平<55mg/dL的患者占32.6%。血压达标的患者占39.2%。糖尿病患者占27.5%，其中43.5%的患者糖化血红蛋白<7%。他汀类药物的处方率从入院时的69%升至出院/就诊结束时的96%。74.
